Skip to main content

Table 2 Comparisons of change in clinical manifestations at baseline and 6 months

From: Prospective clinical trial of Intravitreal aflibercept treatment for PolypoIdal choroidal vasculopathy with hemorrhage or exudation (EPIC study): 6 month results

Patients

ETDRS letters baseline

ETDRS letters 6 months

CFT baseline (μM)

CFT 6 months (μM)

Polyps At 6 months (ICG)

BVN At 6 months (ICG)

1

71

70

210

199

=

=

2

30

60

176

119

↓

=

3

72

68

230

235

R

=

4

75

73

398

177

=

=

5

48

49

276

218

↓

=

6

75

68

318

188

=

=

7

58

72

278

289

=

=

8

59

68

352

343

=

=

9

74

83

237

227

R

=

10

82

80

550

198

↓

↓

11

80

81

249

183

R

=

12

38

37

208

193

↓

=

13

60

67

317

227

R

=

14

36

38

387

163

↓

=

15

83

80

223

200

=

=

16

73

77

222

221

↑

=

17

74

76

346

220

R

=

18

89

83

196

178

↓

=

19

74

73

290

223

↓

=

20

61

70

315

190

↓

=

21

67

64

164

158

R

=

  1. CFT Central foveal thickness, ETDRS: Early Treatment Diabetic Retinopathy Study, BVN: Branching vascular network, ICG: Indocyanine green angiography, ↑ = increased, ↓ = decreased, = =stable, R regressed